Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Accounts Payables (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Accounts Payables for 12 consecutive years, with $646000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accounts Payables fell 54.57% year-over-year to $646000.0, compared with a TTM value of $646000.0 through Sep 2025, down 54.57%, and an annual FY2024 reading of $1.1 million, down 25.38% over the prior year.
  • Accounts Payables was $646000.0 for Q3 2025 at CytomX Therapeutics, up from $227000.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $5.2 million in Q3 2022 and bottomed at $227000.0 in Q2 2025.
  • Average Accounts Payables over 5 years is $1.7 million, with a median of $1.7 million recorded in 2023.
  • The sharpest move saw Accounts Payables surged 241.42% in 2022, then crashed 85.95% in 2025.
  • Year by year, Accounts Payables stood at $2.8 million in 2021, then decreased by 0.32% to $2.8 million in 2022, then crashed by 48.1% to $1.5 million in 2023, then decreased by 25.38% to $1.1 million in 2024, then tumbled by 40.62% to $646000.0 in 2025.
  • Business Quant data shows Accounts Payables for CTMX at $646000.0 in Q3 2025, $227000.0 in Q2 2025, and $276000.0 in Q1 2025.